---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106544"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:26:07.636835+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China

## Summary
- Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
- Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.
- R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.
- Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.
- Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M.

## SEC filing metadata
- accession: 0000950170-25-106544
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/0000950170-25-106544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/tpst-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106544
- JSON: https://secwatch.observer/filing/0000950170-25-106544.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.